Literature DB >> 18462848

Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus.

Xiao Wang1, Xinyu Zhang, Youming Kang, Huali Jin, Xiaogang Du, Gan Zhao, Yang Yu, Jinyao Li, Baowei Su, Chang Huang, Bin Wang.   

Abstract

Aerosol transmission of foot and mouth disease virus (FMDV) is believed to be an important route of infection. Induction of mucosal response is thought to be effective way against such infection. Various approaches have been developed including the use of molecules adjuvant and polymers delivery for the mucosal delivery of DNA vaccine. In this study, using low molecular weight chitosan as a delivery vehicle, we investigated whether co-administration intranasally of the FMDV DNA vaccine, pcD-VP1 and a construct expressing IL-15 as the molecular adjuvant can enhance mucosal and systemic immune responses in animals. Compared to the group intranasally immunized with pcD-VP1 alone, the group immunized with the molecular adjuvant not only was induced higher level of mucosal sIgA but also serum IgG. Interestingly, intranasal delivery of the IL-15 construct with pcD-VP1 significantly enhanced the cell-mediated immunity (CMI) compared to the pcD-VP1 alone, as evidenced by the higher level of antigen-specific T-cell proliferation, cytotoxic T lymphocyte (CTL) response and higher expressions of IFN-gamma in both CD4+ and CD8+ T cells inform the spleen and mucosal sites. Consistently, IL-15 as adjuvant provided higher level of FMDV neutralizing antibody against FMDV and high secretions of IgA producing cells in mucosal tissues. Taken together, the results demonstrated that intranasal delivery of IL-15 as a mucosal adjuvant can enhance the antigen-specific mucosal and systemic immune responses, which may provide a protection against the FMDV initial infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18462848     DOI: 10.1016/j.vaccine.2008.03.088

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus.

Authors:  Hiroyuki Kayamuro; Yasuo Yoshioka; Yasuhiro Abe; Shuhei Arita; Kazufumi Katayama; Tetsuya Nomura; Tomoaki Yoshikawa; Ritsuko Kubota-Koketsu; Kazuyoshi Ikuta; Shigefumi Okamoto; Yasuko Mori; Jun Kunisawa; Hiroshi Kiyono; Norio Itoh; Kazuya Nagano; Haruhiko Kamada; Yasuo Tsutsumi; Shin-ichi Tsunoda
Journal:  J Virol       Date:  2010-09-29       Impact factor: 5.103

Review 2.  Technologies for enhanced efficacy of DNA vaccines.

Authors:  Fadi Saade; Nikolai Petrovsky
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

3.  Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen a protects mice against nasopharyngeal colonization by Streptococcus pneumoniae.

Authors:  Jianghong Xu; Wenjia Dai; Zhengmin Wang; Bing Chen; Zhongming Li; Xiaoyong Fan
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

Review 4.  Non-invasive administration of biodegradable nano-carrier vaccines.

Authors:  Mohd Abul Kalam; Abdul Arif Khan; Aws Alshamsan
Journal:  Am J Transl Res       Date:  2017-01-15       Impact factor: 4.060

5.  Mucosal co-immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan-DNA vaccine against coxsackievirus B3-induced myocarditis.

Authors:  Dafei Chai; Yan Yue; Wei Xu; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2014-03-10       Impact factor: 3.452

6.  Chitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines.

Authors:  Caitlin D Lemke; Jessica B Graham; Sean M Geary; Gideon Zamba; David M Lubaroff; Aliasger K Salem
Journal:  Mol Pharm       Date:  2011-08-09       Impact factor: 4.939

Review 7.  Developments in Vaccine Adjuvants.

Authors:  Farrhana Ziana Firdaus; Mariusz Skwarczynski; Istvan Toth
Journal:  Methods Mol Biol       Date:  2022

8.  Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits.

Authors:  Jia Liu; Sonia Wennier; Mary Reinhard; Edward Roy; Amy MacNeill; Grant McFadden
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

Review 9.  Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccines.

Authors:  Kosuke Kataoka; Kohtaro Fujihashi
Journal:  Expert Rev Vaccines       Date:  2009-09       Impact factor: 5.217

Review 10.  DNA vaccines in veterinary use.

Authors:  Laurel Redding; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2009-09       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.